Evaluation of Therapeutic Effect of Descurainia sophia on the patients with hyperthyroidism

Early Phase 1

Recruiting

• Conditions: Hyperthyroidism.; Thyrotoxicosis, unspecified; E05.9

• Registration Number: IRCT20130911014630N6
• Lead Sponsor: Sari University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 16

Inclusion Criteria

Age between twenty to sixty years
Patients with a higher level of FT4 hormones have a parity of 17 pg /L
Patients with a FT3 serum level Larger than equal to 5.7 pg/ml
Patients with a lower serum TSH level equal to MU / I0.4

Exclusion Criteria

Patients with a history of underlying illness, such as diabetes or hypertension or liver failure, such as cirrhosis of the liver and kidney or heart disease, according to patients referenced
Use other medications
Use cigarettes right now
Alcoholism
Pregnant patients
Lactating patients
Patients who have taken an antithyroid drug for the last three months
Patient with ALT levels are twice the normal range
Patients who are required to receive other medications for the treatment of other illness during the study
Patients who experience side effects such as itching or headache or allergies to the drug
Requesting a patient or his family to leave the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of thyroid hormones. Timepoint: First of the study (before the intervention) and 30, 60 and 90 days after the start of the capsule. Method of measurement: Collection of questionnaires and laboratory tests and periodic clinical examinations.